Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: A randomized active-controlled trial

Journal of Hypertension

Volumn 30, Issue 10, 2012, Pages 2047-2055

  Lacourcière, Yves ^a   Taddei, Stefano ^b   Konis, George ^c   Fang, Hui ^d   Severin, Thomas ^d   Zhang, Jack ^d  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF PISA   (Italy)

^c Woodland International Research Group Inc   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

aliskiren; ambulatory blood pressure; amlodipine; clinic blood pressure; dual combination; hydrochlorothiazide; hypertension; triple combination

Indexed keywords

ALISKIREN; AMLODIPINE; HYDROCHLOROTHIAZIDE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SITTING; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 84866541577     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328356b8ea     Document Type: Article

References (26)

1. Weitzman D, Goldbourt U. The significance of various blood pressure indices for long-term stroke, coronary heart disease, and all-cause mortality in men: the Israeli Ischemic Heart Disease study. Stroke 2006; 37:358-363.
2. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure-overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
3. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelineson hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009; 18:308-347.
4. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, et al. VALUE trial: long-term blood pressure trends in 13449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16:544-548.
5. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646-661.
6. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-h blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5:93-98.
7. Pessina AC, Palatini P, Sperti G, Cordone L, Libardoni M, Mos L, et al. Evaluation of hypertension and related target organ damage by average day-time blood pressure. Clin Exp Hypertens A 1985; 7:267-278.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
9. Littlejohn TW 3rd, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Longterm safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009; 25:951-959.
10. Baldwin CM, Plosker GL. Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension. Drugs 2009; 69:833-841.
11. Blumenstein M, Romaszko J, Calderon A, Andersen K, Ibram G, Liu Z, et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are nonresponsive to HCT 25mg alone. Curr Med Res Opin 2009; 25:903-910.
12. Chrysant SG. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. Expert Rev Cardiovasc Ther 2008; 6:305-314.
13. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18:139-185.
14. Wojciechowski D, Papademetriou V. Does rapidity of blood pressure lowering affect outcomes in hypertension treatment. Curr Cardiovasc Risk Rep 2008; 2:255-261.
15. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
16. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4:393-404.
17. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53:646-653.
18. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihyper-tensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009; 54:32-39.
19. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010; 32:1252-1269.
20. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-719.
21. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111:1777-1783.
22. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension 2007; 49:1265-1270.
23. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46:156-161.
24. Pickering TG, White WB. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2008; 2:119-124.
25. Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien ET, Fagard R. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. JAMA 1997; 278:1065-1072.
26. Murray A, Koenig W, Garcia-Puig J, Patel S, Uddin M, Zhang J. Long-term therapy with aliskiren/amlodipine/hydrochlorothiazide combination provides effective blood pressure reduction with good tolerability in patients with moderate to severe hypertension [poster 54]. J Clin Hypertens 2010; 12 (Suppl 1):A41.